Targeting the arginine metabolic brake enhances immunotherapy for leukaemia

Mussai, F. et al. (2019) Targeting the arginine metabolic brake enhances immunotherapy for leukaemia. International Journal of Cancer, 145(8), pp. 2201-2208. (doi: 10.1002/ijc.32028) (PMID:30485425) (PMCID:PMC6767531)

195484.pdf - Published Version
Available under License Creative Commons Attribution.



Therapeutic approaches which aim to target Acute Myeloid Leukaemia through enhancement of patients’ immune responses have demonstrated limited efficacy to date, despite encouraging preclinical data. Examination of AML patients treated with azacitidine (AZA) and vorinostat (VOR) in a Phase II trial, demonstrated an increase in the expression of Cancer‐Testis Antigens (MAGE, RAGE, LAGE, SSX2 and TRAG3) on blasts and that these can be recognised by circulating antigen‐specific T cells. Although the T cells have the potential to be activated by these unmasked antigens, the low arginine microenvironment created by AML blast Arginase II activity acts a metabolic brake leading to T cell exhaustion. T cells exhibit impaired proliferation, reduced IFN‐γ release and PD‐1 up‐regulation in response to antigen stimulation under low arginine conditions. Inhibition of arginine metabolism enhanced the proliferation and cytotoxicity of anti‐NY‐ESO T cells against AZA/VOR treated AML blasts, and can boost anti‐CD33 Chimeric Antigen Receptor‐T cell cytotoxicity. Therefore, measurement of plasma arginine concentrations in combination with therapeutic targeting of arginase activity in AML blasts could be a key adjunct to immunotherapy.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Keeshan, Dr Karen
Authors: Mussai, F., Wheat, R., Sarrou, E., Booth, S., Stavrou, V., Fultang, L., Perry, T., Kearns, P., Cheng, P., Keeshan, K., Craddock, C., and De Santo, C.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:International Journal of Cancer
Publisher:John Wiley and Sons
ISSN (Online):1097-0215
Published Online:28 November 2018
Copyright Holders:Copyright © 2018 The Authors
First Published:First published in International Journal of Cancer 145(8):2201-2208
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record